Table 4. Pretreatment clinical findings of the study population.
| Causes of failures | Phaco group (58 eyes) | Medication group | p value | |||
|---|---|---|---|---|---|---|
| Owner-led (48 eyes) | Vet-led (44 eyes) | Total (92 eyes) | ||||
| Cataract stage | 0.076 | |||||
| Immature | 17 (29.3) | 7 (14.6) | 5 (11.4) | 12 (13.0) | ||
| Mature | 41 (70.7) | 37 (77.1) | 35 (79.5) | 72 (78.3) | ||
| Hypermature | 0 (0.0) | 4 (8.3) | 4 (9.1) | 8 (8.7) | ||
| Presence of aqueous flare | 21 (36.2) | 17 (35.4) | 24 (54.5) | 41 (44.6) | 0.312 | |
| Presence of lens capsule rupture | 9 (15.5) | 0 (0.0) | 2 (4.5) | 2 (2.2) | 0.009 | |
| Poor glycemic control | 32 (55.2) | 28 (58.3) | 38 (86.4) | 66 (71.7) | 0.042 | |
| Concurrent systemic disease | 22 (37.9) | 30 (62.5) | 31 (70.5) | 61 (66.3) | 0.001 | |
| Diabetes duration (months) | 2 (0.75–4) | 4 (1–11) | 3 (0.25–6) | 3 (1–8) | 0.129 | |
Values are presented as median (interquartile range) or number of eyes (%).
Statistically significant (p < 0.05) associations between the phaco group and medication group using a generalized linear mixed model are shown in bold.